Trial Profile
A Multicenter, Randomized, Double-blind Trial of Brexpiprazole Versus Placebo for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Bipolar I disorders
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 29 Feb 2020 Results published in the European Clinical Trials Database Trial Registry
- 14 Feb 2019 Primary endpoint (Change from baseline in Young-Mania Rating Scale (YMRS) Score) has not been met, as per the results presented in a Lundbeck media release.
- 14 Feb 2019 Results presented in a Lundbeck media release.